CompletedEUCTR 2004-002626-22

Duloxetine 60 to 120 mg Once Daily Compared with Placebo in the Prevention of Relapse in Generalized Anxiety Disorder

This historical record does not confirm current site availability.

Historical research recordAustria + Germany

The study in practice

Understand this study

What did researchers investigate?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Listed locations: Austria · Germany
Study phase: Phase 3

Get this study by email

Study clarity

Study information

Study start dateNot clearly listed

Recruitment status: Completed
Enrollment listed in the registry: 760
Sponsor: Eli Lilly and Company Limited
Sponsor type: Other organization
Study type: Drug
Intervention type: Drug
Study phase: Phase 3
Locations: Austria, Germany
Age range: Not clearly listed
Official registry ID: EUCTR 2004-002626-22
Official title: Show the full official title
Duloxetine 60 to 120 mg Once Daily Compared with Placebo in the Prevention of Relapse in Generalized Anxiety Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Austria · Germany

Registry details

Historical country statuses

Austria — Completed
Germany — Completed

Interested in joining this study?

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Eli Lilly and Company Limited.

Want to explore more studies?

Explore studies